IL128234A0 - Hsv strain lacking functional icp27 and icp34.5 genes - Google Patents

Hsv strain lacking functional icp27 and icp34.5 genes

Info

Publication number
IL128234A0
IL128234A0 IL12823497A IL12823497A IL128234A0 IL 128234 A0 IL128234 A0 IL 128234A0 IL 12823497 A IL12823497 A IL 12823497A IL 12823497 A IL12823497 A IL 12823497A IL 128234 A0 IL128234 A0 IL 128234A0
Authority
IL
Israel
Prior art keywords
genes
strain lacking
lacking functional
hsv strain
functional icp27
Prior art date
Application number
IL12823497A
Other languages
English (en)
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of IL128234A0 publication Critical patent/IL128234A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12823497A 1996-07-26 1997-07-25 Hsv strain lacking functional icp27 and icp34.5 genes IL128234A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9615794.6A GB9615794D0 (en) 1996-07-26 1996-07-26 Mutant herpes simplex virus strains and uses thereof
PCT/GB1997/002017 WO1998004726A1 (en) 1996-07-26 1997-07-25 Hsv strain lacking functional icp27 and icp34.5 genes

Publications (1)

Publication Number Publication Date
IL128234A0 true IL128234A0 (en) 1999-11-30

Family

ID=10797598

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12823497A IL128234A0 (en) 1996-07-26 1997-07-25 Hsv strain lacking functional icp27 and icp34.5 genes

Country Status (11)

Country Link
US (1) US6248320B1 (de)
EP (1) EP0920523B1 (de)
JP (1) JP2000516809A (de)
AT (1) ATE251672T1 (de)
AU (1) AU726645B2 (de)
CA (1) CA2262010C (de)
DE (1) DE69725452T2 (de)
GB (1) GB9615794D0 (de)
IL (1) IL128234A0 (de)
NZ (1) NZ333901A (de)
WO (1) WO1998004726A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041873A1 (en) * 1997-03-14 1998-09-24 The University Court Of The University Of Glasgow Methods for identifying cell cycle regulators
WO1999005272A1 (en) * 1997-07-25 1999-02-04 Neurovex Limited Use of transcription factor brn-3a
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US6713067B2 (en) 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
GB0009079D0 (en) * 2000-04-12 2000-05-31 Neurovex Ltd Herpes viruses for immune modulation
GB9816856D0 (en) * 1998-08-03 1998-09-30 Univ London Cell lines for virus growth
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
GB9930419D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
GB2375113B (en) * 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
US7514110B1 (en) 2000-09-21 2009-04-07 Basf Aktiengesellschaft Talaromyces xylanases
AU1788502A (en) * 2000-11-28 2002-06-11 Univ Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
EP1381280B1 (de) 2001-03-27 2011-05-11 Catherex, Inc. Virusvektoren und ihre verwendung bei therapeutischen methoden
US7430753B2 (en) * 2002-03-27 2008-09-30 At&T Intellectual Property, I, L.P. Method to enable cooperative processing and resource sharing between set-top boxes, personal computers, and local devices
TWI328612B (en) 2002-07-25 2010-08-11 Dsm Ip Assets Bv Genes and their encoded polypeptides involved in the biosynthetic pathway of vitamin b12, vectors and host cells comprising the genes, and process for producing vitamin b12
US20040229362A1 (en) * 2003-05-15 2004-11-18 Alberto Epstein Method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus & the cells used in this method, the corresponding genetic tools, as well as the applications of these non-pathogenic amplicon vectors
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
AU2005232665B2 (en) * 2004-04-08 2010-05-13 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
AU2005302408B2 (en) * 2004-10-28 2012-08-09 The Government of the United States of America as represented by the Department of Veterans Affairs Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
AR060565A1 (es) * 2006-04-21 2008-06-25 Dow Agrosciences Llc Vacuna para la gripe aviaria y metodos de uso
US9085777B2 (en) * 2006-05-11 2015-07-21 Virttu Biologics Limited Mutant HSV, materials and methods for generation of mutant HSV
EP2097517B1 (de) 2006-10-16 2014-06-04 Genelux Corporation Rekombinantes Lister-Stamm Vaccinia Virus kodierend für einen einzelkettigen anti-VEGF Antikörper
EP2144632B1 (de) 2007-05-09 2016-11-16 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Synthetische herpes-simplex-viren typ 1 zur tumorbehandlung
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
AU2016403583B2 (en) 2016-04-22 2020-05-28 Immvira Co., Limited Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
WO2018161825A1 (zh) * 2017-03-09 2018-09-13 厦门大学 一种重组单纯疱疹病毒及其用途
AU2023319760A1 (en) * 2022-08-05 2025-02-13 Immvira Biopharmaceuticals Co., Limited Replication incompetent herpes simplex virus type 1 viral vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
CA2039921A1 (en) * 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
JP3974167B2 (ja) 1992-03-31 2007-09-12 アーチ デベロプメント コーポレイション 遺伝子，腫瘍及びウイルス感染の治療，並びにプログラムされた細胞死（アポプトーシス）を予防するための方法及び組成物
WO1994003207A1 (en) 1992-07-31 1994-02-17 President And Fellows Of Harvard College Herpesvirus vaccines
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
AU6964596A (en) 1995-09-11 1997-04-01 Arch Development Corporation Materials and methods for treating neurodegenerative diseases and for screening for candidate apoptosis inhibitors and inducers

Also Published As

Publication number Publication date
US6248320B1 (en) 2001-06-19
WO1998004726A1 (en) 1998-02-05
CA2262010C (en) 2010-08-31
DE69725452D1 (de) 2003-11-13
EP0920523A1 (de) 1999-06-09
CA2262010A1 (en) 1998-02-05
DE69725452T2 (de) 2004-08-19
JP2000516809A (ja) 2000-12-19
AU726645B2 (en) 2000-11-16
EP0920523B1 (de) 2003-10-08
NZ333901A (en) 2001-05-25
GB9615794D0 (en) 1996-09-04
AU3700797A (en) 1998-02-20
ATE251672T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
IL128234A0 (en) Hsv strain lacking functional icp27 and icp34.5 genes
GB2353529A (en) Mutant herpes simplex viruses and uses thereof
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
IL126804A0 (en) Formulation for use in the prevention of pathogen induced diseases including hiv and hsv
PL324313A1 (en) 10-axcyloxy 10,11-dihydrobenz/b,f/azepin-5-carboxyamides useful in treating nervous system disorders
DE69400208D1 (en) Olionukleotidalkylphosphonate und -phosphonothioate
WO2001053505A3 (en) Herpes virus strains for gene therapy
EP0831836A4 (de) Synthetische katalytisch freie-radikalfänger zur verwendung als antioxydantien zur vorbeugung und heilung von krankheiten
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
WO1996003997A3 (en) Treatment of cancer using hsv mutant
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
BG104466A (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
WO1995003406A3 (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
GB2359083A (en) Mutant herpes simplex viruses and uses thereof
AU5298699A (en) Dnazymes and methods for treating hpv-related disorders
EP0714511A4 (de) Verfahren zur feststellung und bekämpfung von störungen des zentralnervensystems
EP0811687A3 (de) Polypeptiden mit L-Asparaginase Aktivität
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
Gloriosc et al. Herpesvirus gene vectors and applications to human gene therapy
EP0891778A3 (de) Mittel für Vorbeugung und/oder Behandlung von strahlungsinduzierter Störungen
Pinto Locational pattern of office activity in Bangkok: an economic analysis
AUPM293993A0 (en) Treatment and rehabilitation of the elderly so as to bring about renewed vitality and to prevent the onset of alzheimers disease on those with genetic predisposition to it
MXPA02000485A (es) 2-amino-benzoxazinonas para el tratamiento del virus de herpes simple.
Warner Can cognitive theory differentiate persons who have personality traits that are central to the cluster B and the cluster C personality disorders?